Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 18 04:00PM ET
4.83
Dollar change
+0.45
Percentage change
10.27
%
Index- P/E- EPS (ttm)-0.94 Insider Own11.41% Shs Outstand89.94M Perf Week18.97%
Market Cap434.39M Forward P/E- EPS next Y-0.86 Insider Trans-0.20% Shs Float79.82M Perf Month31.97%
Income-83.59M PEG- EPS next Q-0.26 Inst Own44.18% Short Float4.47% Perf Quarter408.42%
Sales0.16M P/S2714.95 EPS this Y-6.55% Inst Trans-1.72% Short Ratio0.76 Perf Half Y478.37%
Book/sh1.51 P/B3.20 EPS next Y13.42% ROA-43.54% Short Interest3.57M Perf Year360.00%
Cash/sh1.51 P/C3.19 EPS next 5Y11.98% ROE-48.59% 52W Range0.75 - 4.65 Perf YTD38.79%
Dividend Est.- P/FCF- EPS past 5Y8.31% ROI-61.28% 52W High3.87% Beta0.37
Dividend TTM- Quick Ratio6.33 Sales past 5Y347.46% Gross Margin- 52W Low544.00% ATR (14)0.32
Dividend Ex-Date- Current Ratio6.33 EPS Y/Y TTM2.64% Oper. Margin-58380.50% RSI (14)72.93 Volatility7.82% 6.94%
Employees72 Debt/Eq0.01 Sales Y/Y TTM-85.98% Profit Margin-52574.84% Recom1.00 Target Price9.40
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q5.76% Payout- Rel Volume0.98 Prev Close4.38
Sales Surprise-91.67% EPS Surprise-10.17% Sales Q/Q136.36% EarningsNov 07 BMO Avg Volume4.70M Price4.83
SMA2017.40% SMA5042.16% SMA200215.03% Trades Volume4,619,909 Change10.27%
Date Action Analyst Rating Change Price Target Change
May-23-23Initiated Robert W. Baird Outperform $7
Sep-07-22Initiated CapitalOne Overweight $7
Apr-29-21Initiated Maxim Group Buy $20
Apr-23-21Resumed Cowen Outperform $10 → $18
Mar-31-21Initiated Wedbush Outperform $21
Mar-31-21Initiated Jefferies Buy $21
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Today 04:01PM
07:00AM
Jan-29-25 04:15PM
Jan-24-25 04:01PM
Jan-13-25 04:21PM
07:00AM Loading…
07:00AM
Dec-30-24 07:00AM
Dec-10-24 01:51PM
09:39AM
Dec-09-24 04:01PM
Dec-06-24 04:01PM
Nov-11-24 07:00AM
Nov-08-24 02:22AM
02:12AM
Nov-07-24 08:35AM
07:35AM Loading…
07:35AM
07:00AM
Nov-06-24 07:50AM
Nov-01-24 07:00AM
Oct-18-24 04:31PM
Sep-03-24 07:00AM
Aug-30-24 04:05PM
Aug-14-24 06:14AM
Aug-13-24 08:15AM
07:14AM
07:00AM
Aug-06-24 08:45AM
07:00AM
Jul-05-24 04:05PM
May-30-24 07:00AM
10:23AM Loading…
May-02-24 10:23AM
03:09AM
May-01-24 11:58PM
12:54PM
07:33AM
07:00AM
Apr-24-24 07:00AM
Apr-16-24 04:05PM
Mar-21-24 07:00AM
Mar-01-24 09:06AM
Feb-29-24 11:25PM
08:11AM
07:27AM
07:00AM
Feb-27-24 07:00AM
Feb-22-24 07:00AM
Dec-29-23 07:00AM
Dec-04-23 07:00AM
Nov-24-23 07:00AM
Nov-16-23 07:00AM
Nov-03-23 09:12AM
01:34AM
Nov-02-23 10:08AM
07:10AM
07:00AM
Oct-26-23 07:00AM
Oct-23-23 10:08AM
Sep-05-23 07:00AM
Aug-16-23 10:05AM
Aug-11-23 06:15AM
Aug-03-23 08:25AM
07:19AM
07:00AM
Jul-31-23 07:54AM
Jul-30-23 02:17PM
Jul-28-23 04:19PM
Jul-27-23 10:53AM
07:00AM
06:00AM
Jul-11-23 08:53PM
Jun-28-23 02:58PM
Jun-27-23 04:05PM
Jun-01-23 08:04PM
May-31-23 04:01PM
May-25-23 07:00AM
May-05-23 06:11AM
May-04-23 08:25AM
07:17AM
07:00AM
Apr-27-23 07:00AM
Apr-18-23 04:01PM
Mar-29-23 10:13AM
09:35AM
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
07:00AM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
Dec-12-22 01:41PM
Dec-08-22 05:00PM
Nov-29-22 12:00PM
Nov-10-22 04:30PM
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melemed Allen S.CHIEF MEDICAL OFFICERFeb 13 '25Sale4.503,06513,799152,875Feb 14 05:50 PM
Andriole Michael T.PRESIDENT AND CEOFeb 13 '25Sale4.527,37033,282609,603Feb 14 05:49 PM
Alrutz Michael AlbertSVP AND GENERAL COUNSELFeb 13 '25Sale4.521,6007,226213,596Feb 14 05:48 PM
Jakeman DavidVP OF FINANCE AND ACCOUNTINGFeb 13 '25Sale4.533001,360148,987Feb 14 05:47 PM
LaSpaluto MichelleCHIEF FINANCIAL OFFICERFeb 13 '25Sale4.512,26010,196172,977Feb 14 05:45 PM
Allen MelemedOfficerFeb 13 '25Proposed Sale4.203,50014,700Feb 13 03:14 PM
Michael AlrutzOfficerFeb 13 '25Proposed Sale4.202,0008,400Feb 13 03:02 PM
Michael AndrioleOfficerFeb 13 '25Proposed Sale4.208,00033,600Feb 13 02:51 PM
Michelle LaSpalutoOfficerFeb 13 '25Proposed Sale4.202,50010,500Feb 13 02:41 PM
Dave JakemanOfficerFeb 13 '25Proposed Sale4.205002,100Feb 13 02:27 PM
Jakeman DavidVP OF FINANCE AND ACCOUNTINGJan 30 '25Sale4.102,80011,470149,287Jan 31 04:40 PM
LaSpaluto MichelleCHIEF FINANCIAL OFFICERJan 30 '25Sale4.111,0154,172175,237Jan 31 04:39 PM
Andriole Michael T.PRESIDENT AND CEOJan 30 '25Sale4.102,3509,636616,973Jan 31 04:38 PM
David JakemanOfficerJan 30 '25Proposed Sale4.003,00012,000Jan 30 01:00 PM
Michael AndrioleOfficerJan 30 '25Proposed Sale4.002,50010,000Jan 30 01:00 PM
Michelle LaSpalutoOfficerJan 30 '25Proposed Sale4.001,1004,400Jan 30 01:00 PM
Michael AndrioleOfficerAug 08 '24Proposed Sale0.871,5001,300Aug 09 01:26 PM
Andriole Michael T.PRESIDENT AND CEOAug 08 '24Sale0.831,2851,065462,453Aug 09 12:01 PM